• Caris Featured in Newsweek Cover Story

    Caris Life Sciences is featured in the latest Newsweek feature/cover story. The article provides an overview of the current state of precision oncology (growing interest and abilities, but underutilized), addresses challenges (doctors lacking expertise in the area and expense/reimbursement issues, clinical trial enrollment for new drugs) and also highlights opportunities – with a keen focus … Read More

  • Caris Life Sciences Showcases Results from Novel Machine Learning Approach to Classify Cancer by Molecular Signatures

    Caris Next Generation Profiling™ enables a proprietary algorithm to accurately classify tumors, demonstrating improvement in cancer diagnosis CHICAGO, Ill., June 1, 2019 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today presented a poster demonstrating how its advanced machine learning approach, Caris Next Generation Profiling™, … Read More

  • Caris Life Sciences Raises $150 Million in Growth Capital from TPG Sixth Street Partners

    Caris to accelerate development of Next Generation Profiling to analyze whole exome, whole transcriptome and the complete cancer proteome using its proprietary artificial intelligence (AI) analytic engine, DEAN, on tens of thousands of patients with mature clinical outcomes Caris is engaged in some of the most important translational research using the proprietary ADAPT Biotargeting System … Read More

  • HonorHealth Research Institute Joins the Precision Oncology Alliance

    Powered by Caris Life Sciences, the POA advances and broadens patient access to precision medicine through comprehensive tumor profiling IRVING, Texas, Sept. 13, 2018 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that the HonorHealth Research Institute has joined Caris’ Precision Oncology Alliance™ … Read More

  • Caris Life Sciences Selected to Perform Genomic Profiling for Hoosier Cancer Research Network Bladder Cancer Study

    IRVING, Texas, August 28, 2018 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that the company has been selected by the Hoosier Cancer Research Network and the study’s sponsor investigator, Dr. Matthew Galsky, to perform genomic tumor profiling for a new Phase II … Read More